Endothelial cells, nitric oxide and ischaemic preconditioning

Basic Research in Cardiology

Volumn 91, Issue 1, 1996, Pages 27-30

  Parratt, J R ^a   Vegh, A ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Bradykinin; cGMP; Endothelial cells; Nitric oxide; Ventricular arrhythmias

Indexed keywords

BRADYKININ; NITRIC OXIDE; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTERY OCCLUSION; CONDITIONING; CORONARY ARTERY; ENDOTHELIUM CELL; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOTHESIS; NONHUMAN; SHORT SURVEY;

ANIMALS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL ISCHEMIA; NITRIC OXIDE; TACHYCARDIA, VENTRICULAR;

EID: 0030053644     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Parratt JR. Vegh A (1994) Pronounced antiarrhythmic effects of ischemic preconditioning. Cardioscience 5: 9-18
2. Vegh A, Komori S. Szekeres L, Parratt JR (1992) Antiarrhythmic effect of preconditioning in anaesthetised dogs and rats. Cardiovasc Res 26: 487-495
3. Piacentini L, Wainwright CL, Parratt JR (1993) The antiarrhythmic effect of ischaemic preconditioning in rat isolated hearts involves a pertussis toxin sensitive mechanism. Cardiovasc Res 27: 674-680
4. Vegh A, Papp JGy, Parratt JR (1994) Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br J Pharmacol 113: 1081-1082
5. Coker SJ, Parratt JR, Ledingham IMcL. Zeitlin IJ (1981) Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291: 323-324
6. Node K, Kitakaze M, Kosaka H, Komamura K, Minamino T, Tada M, Inoue M, Hon M, Kamada T (1995) Plasma nitric oxide end products are increased in the ischemic canine heart. Biochem Biophys Res Commun 211: 370-374
7. Vegh A, Szckeres L, Parratt JR (1992) Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 107: 648-652
8. Vegh A, Papp JGy, Parratt JR (1994) Attenuation of the antiarrhythmic effects of ischaemic preconditioning by blockade of bradykinin B2 receptors. Br J Pharmacol 113: 1167-1172
9. Vegh A, Kaszala K, Papp JGy, Parratt JR (1995) Delayed myocardial protection by pacing-induced preconditioning: a possible role for bradykinin. Br J Pharmacol (in press)
10. Vegh A, Szekeres L, Parratt JR (1990) Protective effects of preconditioning on the ischaemic myocardium involves cyclo-oxygenase products. Cardiovasc Res 24: 1020-1022
11. Kis A, Vegh A, Papp JGy. Parratt JR (1995) Dual blockade of the cyclooxygenase and L-arginine-nitric oxide pathways prevents the antiarrhythmic effects of preconditioning. J Molec Cell Cardiol 27: A159
12. Szilvassy Z, Jakab I, Lonovics J, Papp JGy (1992) Is rapid pacing-induced preconditioning related to changes of myocardial cyclic nucleotide content? J Mol Cell Cardiol 24 (Supp V): S99
13. Parratt JR (1995) Possibilities for the pharmacological exploitation of ischaemic preconditioning. J Mol Cell Cardiol 27: 991-1000
14. Wu Song, Furman BL. Parratt JR (1994) Endotoxin protection against ischaemiainduced ventricular arrhythmias is attenuated by dexamethasone. Br J Pharmac 113: 1083-1084